乳腺卵巢双原发癌研究进展

doi:10.12280/gjfckx.20210185

摘要/Abstract

摘要：

乳腺卵巢双原发癌（double primary breast and ovarian cancer,DPBOC）为女性生殖系统多原发恶性肿瘤（multiple primary malignant neoplasms,MPMNs）常见的一种类型。乳腺、卵巢均为性激素调节器官,两者有着相似的内分泌调节机制。由于乳腺癌患者确诊时多为早期,预后佳,再患原发性卵巢癌的风险较普通女性增高。对散发性乳腺癌或卵巢癌的研究已相对成熟,而DPBOC的发病机制尚不明确,且由于缺乏敏感度及特异度较高的筛查手段,其难以与转移性肿瘤相鉴别,因此较少引起临床医师的关注。综述DPBOC的发病机制、与乳腺癌卵巢转移的鉴别诊断、治疗及预防等,对此类疾病进行深入探讨,使临床医师重视第二原发癌器官的早期监测,对高危人群采取必要的预防措施,抓住最佳治疗时机,尽可能延长双原发癌患者的生存时间。

关键词: 乳腺肿瘤, 卵巢肿瘤, 肿瘤,多原发性, 早期诊断, 诊断,鉴别, 治疗, 乳腺卵巢双原发癌

Abstract:

Double primary breast and ovarian cancer (DPBOC) is a common type of multiple primary malignant neoplasms of the female reproductive system. Both breast and ovary are sex hormone regulating organs, and they have similar endocrine regulating mechanism. Because breast cancer is diagnosed early and has a good prognosis, the risk of primary ovarian cancer is higher than in the general women population. Studies on sporadic breast cancer or ovarian cancer have been relatively mature. However, the pathogenesis of DPBOC is still unclear. Due to the lack of sensitive and specific screening methods, it is difficult to differentiate from metastatic tumors, which has attracted little attention from clinicians. This review will focus on the pathogenesis, differential diagnosis of ovarian metastasis from breast cancer, treatment and prevention of DPBOC. The study may make clinicians pay attention to the early monitoring of the second primary carcinoma organ, take necessary preventive measures for high-risk groups, seize the best treatment opportunity, and prolong the survival time of patients with DPBOC as long as possible.

Key words: Breast neoplasms, Ovarian neoplasms, Neoplasms,multiple primary, Early diagnosis, Diagnosis,differential, Therapy, Double primary breast and ovarian cancer

翟嘉威, 许方玉, 李利. 乳腺卵巢双原发癌研究进展[J]. 国际妇产科学杂志, 2021, 48(6): 615-619.

ZHAI Jia-wei, XU Fang-yu, LI Li. Research Progress of Double Primary Breast and Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(6): 615-619.

参考文献 33

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. doi: 10.3322/caac.21492. doi: 10.3322/caac.21492
[2]	DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019[J]. CA Cancer J Clin, 2019,69(6):438-451. doi: 10.3322/caac.21583. doi: 10.3322/caac.21583
[3]	Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(4):284-296. doi: 10.3322/caac.21456. doi: 10.3322/caac.21456
[4]	Chen C, Xu Y, Huang X, et al. Clinical characteristics and survival outcomes of patients with both primary breast cancer and primary ovarian cancer[J]. Medicine(Baltimore), 2020,99(32):e21560. doi: 10.1097/MD.0000000000021560. doi: 10.1097/MD.0000000000021560
[5]	Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers[J]. JAMA, 2017,317(23):2402-2416. doi: 10.1001/jama.2017.7112. doi: 10.1001/jama.2017.7112 pmid: 28632866
[6]	Shao D, Cheng S, Guo F, et al. Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals[J]. Cancer Sci, 2020,111(2):647-657. doi: 10.1111/cas.14242. doi: 10.1111/cas.14242
[7]	Kwong A, Ho J, Shin VY, et al. Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels[J]. Oncotarget, 2018,9(8):7832-7843. doi: 10.18632/oncotarget.23471. doi: 10.18632/oncotarget.23471 pmid: 29487695
[8]	Rodríguez-Balada M, Roig B, Melé M, et al. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients[J]. Clin Biochem, 2020,76:17-23. doi: 10.1016/j.clinbiochem.2019.11.014. doi: S0009-9120(19)30856-2 pmid: 31786208
[9]	Daly MB, Pilarski R, Yurgelun MB, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020[J]. J Natl Compr Canc Netw, 2020,18(4):380-391. doi: 10.6004/jnccn.2020.0017. doi: 10.6004/jnccn.2020.0017
[10]	Renault AL, Mebirouk N, Fuhrmann L, et al. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers[J]. Breast Cancer Res, 2018,20(1):28. doi: 10.1186/s13058-018-0951-9. doi: 10.1186/s13058-018-0951-9
[11]	Cipriano NM Jr, de Brito AM, de Oliveira ES, et al. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil[J]. Breast Cancer, 2019,26(3):397-405. doi: 10.1007/s12282-018-00938-z. doi: 10.1007/s12282-018-00938-z pmid: 30535581
[12]	Li S, Jiang K, Li J, et al. Estrogen enhances the proliferation and migration of ovarian cancer cells by activating transient receptor potential channel C3[J]. J Ovarian Res, 2020,13(1):20. doi: 10.1186/s13048-020-00621-y. doi: 10.1186/s13048-020-00621-y
[13]	Chiu HY, Huang CJ, Fan YC, et al. Insomnia But Not Hypnotics Use Associates with the Risk of Breast Cancer: A Population-Based Matched Cohort Study[J]. J Womens Health(Larchmt), 2018,27(10):1250-1256. doi: 10.1089/jwh.2017.6626. doi: 10.1089/jwh.2017.6626
[14]	Engel CL, Rasanayagam MS, Gray JM, et al. Work and Breast Cancer: Recommendations to Address Research Needs[J]. New Solut, 2018,28(1):79-95. doi: 10.1177/1048291118758713. doi: 10.1177/1048291118758713
[15]	Indrielle-Kelly T, Frühauf F, Burgetová A, et al. Diagnosis of endometriosis 1st part - Overview of diagnostic approaches[J]. Ceska Gynekol, 2019,84(4):252-259.
[16]	Li N, Deng Y, Zhou L, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017[J]. J Hematol Oncol, 2019,12(1):140. doi: 10.1186/s13045-019-0828-0. doi: 10.1186/s13045-019-0828-0
[17]	Reinert T, Nogueira-Rodrigues A, Kestelman FP, et al. The Challenge of Evaluating Adnexal Masses in Patients With Breast Cancer[J]. Clin Breast Cancer, 2018,18(4):e587-e594. doi: 10.1016/j.clbc.2018.03.006. doi: 10.1016/j.clbc.2018.03.006
[18]	Bruchim I, Ben-Harim Z, Piura E, et al. Preoperative clinical and radiological features of metastatic ovarian tumors[J]. Arch Gynecol Obstet, 2013,288(3):615-619. doi: 10.1007/s00404-013-2776-1. doi: 10.1007/s00404-013-2776-1 pmid: 23471547
[19]	Hann LE, Lui DM, Shi W, et al. Adnexal masses in women with breast cancer: US findings with clinical and histopathologic correlation[J]. Radiology, 2000,216(1):242-247. doi: 10.1148/radiology.216.1.r00jl15242. doi: 10.1148/radiology.216.1.r00jl15242 pmid: 10887255
[20]	Lamovec J, Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study[J]. J Surg Oncol, 1991,48(1):28-33. doi: 10.1002/jso.2930480106. doi: 10.1002/jso.2930480106 pmid: 1653879
[21]	Abd El hafez A, Monir A. Diagnostic spectrum of ovarian masses in women with breast cancer; magnetic resonance imaging: histopathology correlation[J]. Ann Diagn Pathol, 2013,17(5):441-447. doi: 10.1016/j.anndiagpath.2013.06.003. doi: 10.1016/j.anndiagpath.2013.06.003 pmid: 23891503
[22]	Peters IT, van Zwet EW, Smit VT, et al. Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study[J]. PLoS One, 2017,12(1):e0168277. doi: 10.1371/journal.pone.0168277. doi: 10.1371/journal.pone.0168277
[23]	车利, 任军, 邸立军, 等. GCDFP-15对乳腺癌卵巢转移的诊断价值[J]. 肿瘤防治研究, 2009,36(11):944-949. doi: 10.3971/j.issn.1000-8578.2009.11.012. doi: 10.3971/j.issn.1000-8578.2009.11.012
[24]	Espinosa I, Gallardo A, D′Angelo E, et al. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases[J]. Int J Gynecol Pathol, 2015,34(3):257-265. doi: 10.1097/PGP.0000000000000155. doi: 10.1097/PGP.0000000000000155 pmid: 25844549
[25]	李宁, 吴令英, 张蓉, 等. 遗传性乳腺癌卵巢癌91例临床分析[J]. 中华肿瘤杂志, 2005,27(4):245-247. doi: 10.3760/j.issn:0253-3766.2005.04.017. doi: 10.3760/j.issn:0253-3766.2005.04.017
[26]	Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis[J]. J Clin Oncol, 2013,31(33):4188-4198. doi: 10.1200/JCO.2013.48.9021. doi: 10.1200/JCO.2013.48.9021
[27]	Kotsopoulos J, Lubinski J, Moller P, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers[J]. Breast Cancer Res Treat, 2014,143(3):579-586. doi: 10.1007/s10549-013-2823-4. doi: 10.1007/s10549-013-2823-4
[28]	Marchetti C, De Felice F, Palaia I, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers[J]. BMC Womens Health, 2014,14:150. doi: 10.1186/s12905-014-0150-5. doi: 10.1186/s12905-014-0150-5 pmid: 25494812
[29]	Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality[J]. JAMA, 2010,304(9):967-975. doi: 10.1001/jama.2010.1237. doi: 10.1001/jama.2010.1237 pmid: 20810374
[30]	Choi YH, Terry MB, Daly MB, et al. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants[J]. JAMA Oncol, 2021,7(4):585-592. doi: 10.1001/jamaoncol.2020.7995. doi: 10.1001/jamaoncol.2020.7995
[31]	Chae S, Kim EK, Jang YR, et al. Effect of risk-reducing salpingo-oophorectomy on quality of life in Korean BRCA mutation carriers[J]. Asian J Surg, 2021,44(8):1056-1062. doi: 10.1016/j.asjsur.2021.01.007. doi: 10.1016/j.asjsur.2021.01.007
[32]	Becaria Coquet J, Caballero VR, Camisasso MC, et al. Diet Quality, Obesity and Breast Cancer Risk: An Epidemiologic Study in Córdoba, Argentina[J]. Nutr Cancer, 2020,72(6):1026-1035. doi: 10.1080/01635581.2019.1664601. doi: 10.1080/01635581.2019.1664601 pmid: 31559865
[33]	Khan S, Ayub H, Khan T, et al. MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer[J]. Biochimie, 2019,167:12-24. doi: 10.1016/j.biochi.2019.09.001. doi: 10.1016/j.biochi.2019.09.001